Opendata, web and dolomites

LIFEOMEGA

Innovative highly concentrated Omega 3 food supplement

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIFEOMEGA project word cloud

Explore the words cloud of the LIFEOMEGA project. It provides you a very rough idea of what is the project "LIFEOMEGA" about.

emulsion    athletes    regulatory    lifeomega    patients    cover    risk    dosages    constitute    15    concentration    germany    dietary    people    necks    uk    ideal    helps    gr    chemotherapy    cardiovascular    chronic    acids    nutrition    ml    musculature    epa    tgs    treatment    mentioned    bottle    fatty    anorexia    grams    retinal    sachet    inflammatory    cancer    spain    supplement    innovation    minimizing    utilized    normally    liquid    plan    requirement    arthritis    omega    fewer    search    million    cachexia    milk    won    market    receiving    unfortunately    permit    juice    weight    acid    consisting    quality    constituted    maintaining    consists    dilution    innovative    extra    economical    cosmetic    ip    reduce    protecting    diseases    permits    italy    competition    liquids    11    pro    life    fats    solution    pharma    commercialization    soup    food    concentrated    france    usa    suffer    nutritional    multiple    meeting    business    supports    clinical    joints    form    sclerosis    emulsions    psoriasis    asthma    saturated    feasibility    maximum   

Project "LIFEOMEGA" data sheet

The following table provides information about the project.

Coordinator
SOLUTEX GC SL 

Organization address
address: CTR DE BARAJAS 24 3-4 PARQUE EMPRESARIAL OMEGA EDIFICIO GAMMA
city: ALCOBENDAS MADRID
postcode: 28108
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.solutex.es
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.3.2. (SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SOLUTEX GC SL ES (ALCOBENDAS MADRID) coordinator 50˙000.00

Map

 Project objective

The project aims to develop an innovative food supplement consisting on a high concentrated emulsion of Omega-3 fatty acid EPA. Omega-3 is utilized as a treatment in psoriasis, arthritis, asthma, multiple sclerosis, chronic inflammatory, cancer, high TGs, retinal diseases and cardiovascular failure.

It consists of 15 ml liquid concentration of EPA, minimizing the level of saturated fats. It’s high concentrated -3 grams EPA/ sachet–, so it allows meeting the nutritional requirements in fewer dosages. Similar products in the market are constituted of maximum 1 gr. EPA, in which a higher concentration means higher level of saturated fats. Liquid form permits the dilution in other liquids, as milk, soup, or juice.

These features permit the following applications: 1) Clinical nutrition: most of cancer patients suffer cachexia or anorexia. EPA supports weight management, reduce the pro-inflammatory response and improve quality of life.

2) Dietary supplement: EPA helps maintaining the musculature and protecting the joints, so it is ideal for competition athletes.

Innovation is present in all aspects: application, as the multiple emulsions technology is applied to food products – normally it is applied in cosmetic or pharma-; product, as there are no products in the market offering such a high EPA concentration in liquid form minimizing the saturated fats; design, as it has liquid form; and solution, as the mentioned features constitute a solution for people having an extra requirement of fatty acids.

Goal in phase I is to develop a feasibility study, including a business plan which will cover all aspects of commercialization of LIFEOMEGA: technical, economical, risk assessment, IP, regulatory, bottle necks, market study, partner search, among others.

LIFEOMEGA has a great potential, as it is estimated that cancer patients receiving chemotherapy unfortunately won’t be less than 1 million/year during the next 11 years, in USA, Spain, France, Germany, UK and Italy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIFEOMEGA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIFEOMEGA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.3.2.)

SCHOCKO3 (2015)

Novel Ozone and Thermal Shock Conservation Process for Vegetables

Read More  

DWAVE (2015)

Designing waves for the people

Read More  

HEALTHSTOCK (2015)

Fodder for for HEALTHier animals and improved liveSTOCK production

Read More